1-4 of 4
Victoria Allgood
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The novel allosteric NEK7 inhibit ofirnoflast (HT-6184) reduces oxidized mitochondrial DNA in patients with low-risk myelodysplastic syndrome

Free
Devan Bursey, Victoria Allgood, Andrea Groen, Jeremiah Bearss, Stephen Anthony, David Bearss
Journal: Blood
Blood (2025) 146 (Supplement 1): 2093.
https://doi.org/10.1182/blood-2025-2093
Published: 2025
Journal Articles

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) suppresses IL-8 and other pro-inflammatory cytokines in patients with low-risk myelodysplastic syndrome and symptomatic anemia

Free
Devan Bursey, Victoria Allgood, Andrea Groen, Jeremiah Bearss, Margit Janat-Amsbury, Stephen Anthony, David Bearss
Journal: Blood
Blood (2025) 146 (Supplement 1): 2092.
https://doi.org/10.1182/blood-2025-2092
Published: 2025
Journal Articles

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia

Free
Varun Bafna, Sandip Shah, Arijit Nag, Prof. Uttam Kumar Nath, Chandran Nair, Ramesh Uppada, Devan Bursey, Andrea Groen, Victoria Allgood, Alan List, Stephen Anthony, David Bearss
Journal: Blood
Blood (2025) 146 (Supplement 1): 5622.
https://doi.org/10.1182/blood-2025-5622
Published: 2025
Journal Articles

TP53 exon 7 (c.742C>T; p. Arg248Trp) vaf suppression by novel oral allosteric NEK7 inhibitor in a patient with low-risk myelodysplastic syndrome in A phase 2 clinical trial

Free
Devan Bursey, Victoria Allgood, Andrea Groen, Jeremiah Bearss, Stephen Anthony, David Bearss
Journal: Blood
Blood (2025) 146 (Supplement 1): 7379.
https://doi.org/10.1182/blood-2025-7379
Published: 2025